Biotronik reports positive long-term data for Orsiro stent

Biotronik has announced new clinical trial data that underlines the long-term benefits offered by its Orsiro drug-eluting stent (DES).

Data from the BIOFLOW-II randomised controlled trial has been presented, showing the  high long-term safety and clinical performance of the device in the treatment of coronary artery stenosis over a 60-month period.

A target leisure failure rate of 10.4 percent was associated with Orsiro, compared to 12.7 percent among those receiving an established competitor stent. Moreover, no definite or probable stent thrombosis occurred during 60 months of follow-up in the Orsiro group.

These findings supplement the existing body of evidence supporting the use of the Orsiro DES, with more than 32,500 patients having been enrolled to date in the Orsiro clinical study programme.

Dr Alexander Uhl, vice-president of marketing for Biotronik's vascular intervention business, said: "Long-term data is critical to the clinical community. We are delighted to be able to report these excellent long-term results, confirming that Orsiro can be considered the new benchmark for DES."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.